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Sir,
I write to congratulate the Authors and the Series Editor,
Professor Naylor, for an excellent article on the medico-
legal aspects of surgical intervention. In my view, this
article should become compulsory reading for Consultants
and Trainees in all surgical specialties. I do hope that this
article will also be read by Lawyers involved with
medico-legal work. Perhaps the article could be re-pub-
lished in a Legal Journal? There should be no impediment
to dual publication as the audiences of the two Journals
are completely different, as long as copyright is
acknowledged.
I disagree with the Authors in only one of their state-
ments. That is that: ‘‘We do not support the claim that
with any new surgical procedure a randomised trial should
begin with the first patient as this could potentially stifle
advancement in surgical technique.’’
I agree that a randomised trial cannot take place until
a new surgical procedureor device has beendeveloped to the
point where a trial seems feasible. However, I disagree that
amonitoring or audit period should bea requirement to enter
a trial. The Authors themselves state that: ‘‘The ‘‘learning
curve’’ needs careful monitoring to ensure safety and effi-
cacy.’’ The best way to monitor this is within the confines of
a randomised controlled trial. Relying on self-reporting or
registries to monitor the ‘‘learning curves’’ can lead to over-
optimistic results caused by a selection bias. Investigators
worry that including the ‘‘learning curve’’ in a randomised
trial might damage their results. This is not the case if
a ‘Tracker Trial’ methodology is used where the results areDOI of original article: 10.1016/j.ejvs.2008.05.006.analysed in a temporal fashion. The data generated from the
early part of such a trial can give valuable information about
the generalisability of the technique, if it subsequently
becomes widely adopted.
I was also disappointed that the Authors did not address
the dilemma posed during the period after a trial ends and
before the results are known. What should a Clinician do
during this time period? The obvious solution is for trials to
include continued funding for randomisation during this
period in their trial design. Clinicians and patients then do
not have to make a difficult decision about which treat-
ment to choose before the results are known and the
additional data can be subsequently added to the main
trial data at a later date.
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questionable practice?’’Sir
We would like to thank Professor J. D. Beard for his
comments and observations on our recent publication
‘‘When does the ‘‘learning curve’’ of innovative interven-
tions become questionable practice? Eur J Vasc Endovasc
Surg 2008; 36: 253e257. These comments are warmly
accepted and provide a welcome insight from a clinical
perspective.
The authors acknowledge Professor Beard’s suggestion
that use of a Tracker Trial methodology might be of benefit
from a clinical viewpoint. We suggest, however, that this
method would be of little benefit when viewed on legal and
ethical grounds, particularly when considered from the
patient perspective.
We agree that in principle, the Tracker Trial method-
ology could offer a useful means of preserving clinical
equipoise and to assist in the early identification of the
surgeon whose performance is not up to the required
standard. This will not, however, be of any benefit to the
first recipients of the new technique. Irrespective of
additional safeguards, proposed in Tracker TrialDOI of original article: 10.1016/j.ejvs.2008.09.021.
122 Correspondencemethodology, the patient is still the recipient of
a procedure that is in its infancy and the problems
associated with ‘the learning curve’ prevail. Thus the
need for adequate information to be given to the patient
remains crucial. By law the patient must be given suffi-
cient information about the proposed procedure and its
inherent risks to enable them to reach an informed
decision. Therefore, the need to disclose the innovative
character of the proposed treatment, as well as the
experience of the operator and the availability of alter-
native treatments, remains of paramount importance
from a legal perspective and to safeguard patient
autonomy.
Finally, Professor Beard raises some very interesting
points in his final paragraph, concerning the dilemma posed
after the trial has ended and before the results are known.
These issues did not fall within the remit of the
article, however we believe that funding for continuedrandomisation in these circumstances is necessary in the
interests of justice.
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